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Background: The Occluded Artery Trial (OAT), a randomized study of routine percutaneous coronary intervention (PCI) or optimal medical therapy 
(MED) alone for the treatment of a totally occluded infarct-related artery (IRA) 3 to 28 days after myocardial infarction in subjects who met a high-
risk criterion (an ejection fraction of <50% or proximal occlusion) did not show any difference in death, reinfarction and congestive heart failure 
(CHF) between study groups after a 3-year mean follow-up. Although the majority of PCI patients were treated with bare metal stents (BMS), drug 
eluting stents (DES) were also implanted in the latter part of the study.
Objectives: To conduct an exploratory analysis of long-term outcomes for DES deployment vs.BMS of the target occlusion in the PCI group vs. MED 
in the OAT.
Methods: We compared the clinical outcomes of PCI patients with DES, BMS and MED. Patients enrolled after February 2003 (when first DES was 
implanted) were analyzed (DES n=79, BMS n=393, MED n=552) up to a maximum follow-up of 6 years (mean survivor follow-up 5.1 years). Pre-
specified level of significance for secondary analyses is p<0.01.
Results: Among the 3 cohorts there were no significant differences in baseline characteristics. The 6 yr occurrence of the composite end-point of 
death, reinfarction and class IV CHF was similar (20.4% of DES, 18.9% of BMS and 18.4% of MED (p=0.66)) as were the rates of the components of 
the primary end-point. During the follow-up period, 33.4% of DES, 44.4% of BMS and 48.1% of MED patients, developed angina (p=0.037). The rate 
of revascularization during follow up was 11.3%, 20.5% and 22.5% among these groups, respectively (p=0.045).
Conclusions: There is no suggestion of reduced long-term risk of death, reinfarction or class IV CHF with DES usage compared to BMS or medical 
treatment alone. An association between DES use and freedom from angina and revascularization relative to medical therapy is suggested. These 
data must be interpreted with caution due to the small number of patients treated with DES and the non-randomized nature of this analysis.
